z-logo
Premium
Triple‐blind, placebo‐controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs
Author(s) -
Wheatley David
Publication year - 2004
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.627
Subject(s) - ginkgo biloba , placebo , antidepressant , medicine , depression (economics) , sexual dysfunction , anxiety , randomized controlled trial , anesthesia , psychology , psychiatry , pharmacology , alternative medicine , pathology , economics , macroeconomics
A triple‐blind (investigator, patient, statistician), randomized, placebo‐controlled, trial of Ginkgo biloba 240 mg daily was carried out. Following a 1‐week control, it was given to 24 patients with sexual impairment due to antidepressant drugs. Efficacy analysis was carried out on eight males and five females on placebo and six males and five females on Ginkgo, completing the full 12 weeks of treatment. Not included were three subjects who dropped out after 6 weeks. A validated, sex (gender)‐orientated questionnaire was recorded at − 1, 0, 1, 3, 6, 9 and 12 weeks, and a non‐blind follow‐up for a further 6‐weeks on Ginkgo. Hamilton anxiety and depression ratings were made at 0, 6 and 12 weeks and simple global assessments of alertness and memory. There were some spectacular individual responses in both groups, but no statistically significant differences, and no differences in side‐effects. Copyright © 2004 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here